<DOC>
	<DOCNO>NCT00006013</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth multiple myeloma stop blood flow cancer cell . PURPOSE : Phase II trial study effectiveness SU5416 treat patient refractory relapse multiple myeloma .</brief_summary>
	<brief_title>SU5416 Treating Patients With Refractory Relapsed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate response duration patient refractory relapse multiple myeloma treat SU5416 . II . Determine toxicity SU5416 patient population . OUTLINE : This multicenter study . Patients receive SU5416 IV 1 hour twice weekly . Treatment continue absence unacceptable toxicity disease progression . Patients follow survival . PROJECTED ACCRUAL : A total 20-38 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma elevate monoclonal protein serum and/or urine No history CNS lesion CNS bleed PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Cytopenias secondary multiple myeloma involvement bone marrow allow Cytopenias due multiple myeloma require : WBC least 3,000/mm3 Platelet count least 75,000/mm3 Hepatic : Transaminases great 2 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No congestive heart failure , severe peripheral vascular disease , significant arrhythmia No poorly control systolic diastolic hypertension No uncompensated coronary artery disease No history myocardial infarction severe/unstable angina within past 6 month No know hypercoagulable state deep venous arterial thrombosis within past 3 month Pulmonary : No pulmonary embolism within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No severe medical psychiatric condition ( e.g. , active peptic ulcer , active infection , history severe alcohol drug abuse ) No know hypersensitivity paclitaxel Cremophor PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy Chemotherapy : At least 1 3 prior chemotherapy regimens Induction follow high dose therapy stem cell support consider single treatment regimen Tandem course high dose therapy consider 2 regimen Endocrine therapy : At least 1 prior regimen contain steroid Radiotherapy : Prior radiotherapy symptom control allow Surgery : At least 3 week since prior major surgery At least 1 year since prior coronary artery surgery , angioplasty , stent placement No prior brain surgery Other : No concurrent investigational drug Concurrent bisphosphonates ( e.g. , pamidronate ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>